Mettler-Toledo MTD
Mettler-Toledo is a global provider of precision instruments and services for laboratories, industries, and process control applications, with a recurring business model based on high-tech equipment and associated services. Mettler-Toledo combines an exceptional moat (ROIC 59.98%, operating margin 31.2%) with solid growth (earnings +18.3%), but its demanding valuation (P/E 34.13, EV/EBITDA 25.38) limits the appeal at current prices.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Mettler-Toledo is a global provider of precision instruments and services for laboratories, industries, and process control applications, with a recurring business model based on high-tech equipment and associated services. Mettler-Toledo combines an exceptional moat (ROIC 59.98%, operating margin 31.2%) with solid growth (earnings +18.3%), but its demanding valuation (P/E 34.13, EV/EBITDA 25.38) limits the appeal at current prices.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.1 |
| Quality / Moat | 8.6 |
| Valuation | 3.1 |
| Growth | 6.4 |
| Dividend | 1.5 |
| Momentum | 5.7 |
| Risk & Context | 4.7 |
OVERALL SCORE: 5.7/10
Context and risks
Domiciled in Switzerland with moderate governance/regulatory risk. No material exposure to current macro factors (rates, oil, tariffs) given its precision instruments business profile.
News considered in the analysis
- Mettler Toledo International (MTD), Why Is It Getting Fresh Attention? — Artículo de análisis genérico sin información nueva sobre la empresa.
- 1 S&P 500 Stock Worth Your Attention and 2 We Ignore — Listículo sin datos concretos que afecten a la valoración.
- What Makes Mettler-Toledo International (MTD) an Attractive Bet? — Opinión de analista sin información nueva.
- 2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds — Comparativa genérica sin impacto específico.
- Is Mettler-Toledo Stock Underperforming the Nasdaq? — Análisis de rendimiento relativo sin información fundamental nueva.
Verdict: Hold; quality is outstanding but the price already discounts much of the expectations.
Main risk: Demanding valuation (P/E 34.13) leaving little room for error if earnings growth decelerates from the current 18.3%.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →